Zydus partners with US-based IDRI for Kala-Azar vaccine

An article from The Economic Times
July 25, 2013
Zydus partners with US-based IDRI for Kala-Azar vaccine

 

July 25, 2013--Indian drugmaker Zydus Cadila has entered into a partnership with the Infectious Disease Research Institute (IDRI), an American non-profit organization, to collaborate on the production and clinical development of IDRI's visceral leishmaniasis (VL) vaccine. To date, no vaccine exists to treat this illness, transmitted by the bite of an infected sandfly, and endemic in 88 countries. There are drugs against visceral leishmaniasis available, but they are expensive and sometimes toxic. The IDRI vaccine is the product of more than 20 years of research, and is supported by the Bill & Melinda Gates Foundation and the U.S. National Institutes of Health (NIH). Read more here.